Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | CTSG | P08311 | 2/20 | 0.32 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.32 |
| ▸ | CMA1 | P23946 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26035275 | 0.77 | CNR1 (0.39) | SMN1; SMN2 | |
| SCHEMBL25849209 | 0.71 | BIRC2 (0.48) | BIRC2 | |
| SCHEMBL24419530 | 0.66 | BIRC2 (0.43) | BIRC2HDAC8HDAC3HDAC6HDAC1 | |
| SCHEMBL24032972 | 0.65 | BIRC2 (0.32) | BIRC2 | |
| SCHEMBL28601020 | 0.64 | CA2 (0.52) | BIRC2HDAC8HDAC6 | |
| SCHEMBL21250702 | 0.64 | CA2 (0.52) | BIRC2HDAC8HDAC6 | |
| SCHEMBL26030776 | 0.64 | CA2 (0.52) | BIRC2HDAC8HDAC6 | |
| SCHEMBL8431170 | 0.64 | CA2 (0.52) | BIRC2HDAC8HDAC6 | |
| SCHEMBL18612532 | 0.64 | CA2 (0.52) | BIRC2HDAC8HDAC6 | |
| SCHEMBL20942699 | 0.63 | CA2 (0.49) | BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | SLC6A5 4369/4885BIRC2 3314/4885PRSS1 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.